Inclusion Criteria:  The participant could, in the opinion of the Investigator, benefit from long-term dapirolizumab pegol (DZP) treatment The participant completed one of the placebo controlled (PBO-controlled) parent studies within 4 weeks prior to entry to this study  Exclusion Criteria:  - Study participant has any medical or psychiatric condition (including conditions due to neuropsychiatric systemic lupus erythematosus (SLE)) that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study. This includes study participants with a life-threatening condition or ongoing malignancies at the start of the study